Abstract |
Data regarding the efficacy and safety of methotrexate (MTX) in adults with localized scleroderma (LoS) is scarce. This study gathered data from a retrospective cohort of adult patients with LoS (n?=?107), treated with MTX (1993-2015). MTX drug survival and predictors thereof were analysed. After 1 and 2 years, 26% and 63% of patients stopped MTX due to disease remission, respectively. Patients with younger age at MTX initiation (hazard ratio (HR) 1.159 (95% confidence interval (CI) 1.052-1.277)) and those with no other autoimmune diseases (HR 3.268 (95% CI 1.334-8.009)) more often stopped MTX due to disease remission. In addition, 24% of patients stopped MTX due to treatment failure within one year. Patients with circumscribed superficial LoS (HR 0.221 (95% CI 0.081-0.601)) experienced treatment failure less often than those with other LoS subtypes. Finally, adding folic acid (HR 0.184 (95% CI 0.079-0.425)) and reducing treatment delay (HR 1.056 (95% CI 1.004-1.112)) could be the most important factors in minimizing MTX treatment failure in LoS in clinical practice.
|
Authors | Jorre S Mertens, Juul M van den Reek, Wietske Kievit, Peter C M van de Kerkhof, Rogier M Thurlings, Tim R D Radstake, Marieke M B Seyger, Elke M G J de Jong |
Journal | Acta dermato-venereologica
(Acta Derm Venereol)
Vol. 96
Issue 7
Pg. 943-947
(Nov 02 2016)
ISSN: 1651-2057 [Electronic] Sweden |
PMID | 26983450
(Publication Type: Journal Article)
|
Chemical References |
- Antirheumatic Agents
- Folic Acid
- Methotrexate
|
Topics |
- Adolescent
- Adult
- Aged
- Antirheumatic Agents
(administration & dosage, adverse effects, therapeutic use)
- Child
- Child, Preschool
- Female
- Folic Acid
(therapeutic use)
- Humans
- Infant
- Male
- Methotrexate
(administration & dosage, adverse effects, therapeutic use)
- Middle Aged
- Remission Induction
- Retrospective Studies
- Scleroderma, Localized
(drug therapy)
- Treatment Outcome
|